Stockscreener 앱 받기
1.50
2.04%
0.03
시간 외 거래:
1.48
-0.02
-1.33%
Medicinova Inc 주식(MNOV)의 최신 뉴스
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth - Yahoo Finance
MediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.com - Defense World
MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025 - The Manila Times
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025 - GlobeNewswire
MediciNova Secures Spotlight at Exclusive Healthcare Conference: CEO to Reveal Latest Pipeline Progress - Stock Titan
Meta CEO Mark Zuckerberg takes the stand in historic antitrust trial - The Globe and Mail
MediciNova’s (MNOV) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Texas Instruments (TXN) Stock Trades Down, Here Is Why - The Globe and Mail
First Patient Enrolled in NIH-Funded Expanded Access - GlobeNewswire
This Stock Has More Than Doubled Already in 2025. Is It a Buy? - The Globe and Mail
MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com - Defense World
MEDICINOVA INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Why AppLovin (APP) Shares Are Trading Lower Today - The Globe and Mail
MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com - The AM Reporter
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com - Defense World
Carter's (CRI): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
3 Reasons to Avoid CSX and 1 Stock to Buy Instead - The Globe and Mail
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV) - Defense World
Idiopathic Pulmonary Fibrosis Management Market Top Companies - openPR
Y Intercept Hong Kong Ltd Makes New $78,000 Investment in MediciNova, Inc. (NASDAQ:MNOV) - Defense World
Should You Forget Tesla and Buy 2 Artificial Intelligence (AI) Stocks Right Now? - The Globe and Mail
StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV) - Defense World
Pulmonary Fibrosis Therapeutics Market Size in the 7MM - openPR
MKS Instruments to Participate in Cantor Fitzgerald Global Technology Conference - The Globe and Mail
Idiopathic Pulmonary Fibrosis Management Market Key Players - openPR
D. Boral Capital Reiterates Buy Rating for MediciNova (NASDAQ:MNOV) - The AM Reporter
MediciNova (NASDAQ:MNOV) Issues Earnings Results - MarketBeat
MediciNova (NASDAQ:MNOV) Releases Quarterly Earnings Results, Meets Estimates - MarketBeat
MediciNova (MNOV) to Release Quarterly Earnings on Thursday - MarketBeat
MediciNova (MNOV) Projected to Post Quarterly Earnings on Thursday - Defense World
Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs - The Globe and Mail
US Exchange Penny Stocks To Watch In January 2025 - Yahoo Finance
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com - Defense World
Jane Street Group LLC Takes $30,000 Position in MediciNova, Inc. (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Share Price Crosses Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
MediciNova, Inc. (NASDAQ:MNOV) Shares Acquired by Geode Capital Management LLC - Defense World
Why Amazon’s Next Earnings Could Trigger a Stock Breakout - The Globe and Mail
MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving Average – Time to Sell? - Defense World
MediciNova (NASDAQ:MNOV) Stock Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
1.00%
자본화:
|
볼륨(24시간):